{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:31:42Z","timestamp":1780417902808,"version":"3.54.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>A 72-year-old woman presented to our hospital with elevation of serum transaminases. Her blood tests showed the hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) negative. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were given for the diffuse large B-cell lymphoma. She didn\u2019t receive anti- hepatitis B virus (HBV) drug for the isolated HBcAb positive. HBV reactivation confirmed based on the serum HBV DNA detectable until 19 months after stopping R-CHOP regimen. HBV DNA became undetectable after 4 weeks therapy with Tenofovir alafenamide fumarate (TAF). Serum transaminases went down to normal 3 months later after receiving TAF. HBV reactivation is a substantial risk for patients with isolated HBcAb positive receiving rituximab-containing chemotherapy without anti- HBV drug. Regular monitoring with a frequency of 1-3 months is the basis for timely diagnosis and treatment of HBV reactivation. Serum transaminases abnormalities may be the initial manifestation of HBV reactivation.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1083862","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:10:10Z","timestamp":1669975810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A case report of hepatitis B virus reactivation 19 months after cessation of chemotherapy with rituximab"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiangjuan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengliang","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological association institute guideline on the prevention and treatment of hepatitis b virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis b: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis b virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3350\/cmh.2019.1002","article-title":"KASL clinical practice guidelines for management of chronic hepatitis b","volume":"25","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1007-3418.2019.12.007","article-title":"The guidelines of prevention and treatment for chronic hepatitis b (2019 version)","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis b reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis b virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis b reactivation in patients with previous hepatitis b virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-017-9817-y","article-title":"Risk of hepatitis b reactivation in HBsAg-negative\/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis","volume":"11","author":"Tang","year":"2017","journal-title":"Hepatol Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e7481","DOI":"10.7717\/peerj.7481","article-title":"Rituximab increases the risk of hepatitis b virus reactivation in non-Hodgkin lymphoma patients who are hepatitis b surface antigen-positive or have resolved hepatitis b virus infection in a real-world setting: a retrospective study","volume":"7","author":"Tsai","year":"2019","journal-title":"Peerj"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with b-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020285","article-title":"HBV reactivation in patients with past infection affected by non-Hodgkin lymphoma and treated with anti-CD20 antibody based immuno-chemotherapy: A multicenter experience","volume":"12","author":"Clerico","year":"2022","journal-title":"J Pers Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","article-title":"Kinetics and risk of de novo hepatitis b infection in HBsAg-negative patients undergoing cytotoxic chemotherapy","volume":"131","author":"Hui","year":"2006","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-induced hepatitis b reactivation in lymphoma patients with resolved HBV infection: A prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5678-20","article-title":"Hepatitis b virus reactivation 55 months following chemotherapy including rituximab and autologous peripheral blood stem cell transplantation for malignant lymphoma","volume":"60","author":"Hara","year":"2021","journal-title":"Intern Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ344","article-title":"Monitoring of hepatitis b virus (HBV) DNA and risk of HBV reactivation in b-cell lymphoma: A prospective observational study","volume":"61","author":"Kusumoto","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.09.014","article-title":"Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA","volume":"50","author":"Nakaya","year":"2016","journal-title":"Leuk Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis b: AASLD 2018 hepatitis b guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316490","article-title":"Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose","volume":"68","author":"Candotti","year":"2019","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Update of the statements on biology and clinical impact of occult hepatitis b virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.05.001","article-title":"Aging of the immune system: how much can the adaptive immune system adapt","volume":"24","author":"Weng","year":"2006","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1241-0","article-title":"Risk of hepatitis b virus (HBV) reactivation in hepatitis b surface antigen negative\/hepatitis b core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis","volume":"90","author":"Koo","year":"2011","journal-title":"Ann Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1083862\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:10:13Z","timestamp":1669975813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1083862\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2022.1083862"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1083862","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"article-number":"1083862"}}